TG Therapeutics, Inc. – NASDAQ:TGTX
TG Therapeutics stock price today
$27.92
-4.60
-14.17%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
TG Therapeutics stock price monthly change
+53.52%
month
TG Therapeutics stock price quarterly change
+53.52%
quarter
TG Therapeutics stock price yearly change
+90.79%
year
TG Therapeutics key metrics
Market Cap | 4.95B |
Enterprise value | 2.87B |
P/E | -15.23 |
EV/Sales | 1033.82 |
EV/EBITDA | -15.30 |
Price/Sales | 1066.27 |
Price/Book | 50.68 |
PEG ratio | -0.34 |
EPS | 0.28 |
Revenue | 289.33M |
EBITDA | 49.21M |
Income | 41.19M |
Revenue Q/Q | 713.45% |
Revenue Y/Y | 3275.73% |
Profit margin | -7121.54% |
Oper. margin | -6924.2% |
Gross margin | 90.48% |
EBIT margin | -6924.2% |
EBITDA margin | 17.01% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTG Therapeutics stock price history
TG Therapeutics stock forecast
TG Therapeutics financial statements
Average Price Target
$37.5
Potential upside: 34.31%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 16.07M | -47.61M | -296.19% |
|---|---|---|---|
| Sep 2023 | 165.81M | 113.93M | 68.71% |
| Dec 2023 | 43.97M | -14.41M | -32.79% |
| Mar 2024 | 63.47M | -10.70M | -16.87% |
| Jun 2023 | 220854000 | 180.40M | 81.68% |
|---|---|---|---|
| Sep 2023 | 331067000 | 166.29M | 50.23% |
| Dec 2023 | 329587000 | 169.08M | 51.3% |
| Mar 2024 | 373323000 | 213.21M | 57.11% |
| Jun 2023 | -42.00M | 30.50M | 47.04M |
|---|---|---|---|
| Sep 2023 | 83.70M | -30.22M | 421K |
| Dec 2023 | -13.21M | -44.75M | -1K |
| Mar 2024 | -8.20M | -9.25M | 10K |
TG Therapeutics alternative data
| Sep 2023 | 244 |
|---|---|
| Oct 2023 | 244 |
| Nov 2023 | 244 |
| Dec 2023 | 245 |
| Jan 2024 | 245 |
| Feb 2024 | 245 |
| Mar 2024 | 264 |
| Apr 2024 | 264 |
| May 2024 | 264 |
| Jun 2024 | 284 |
| Jul 2024 | 284 |
TG Therapeutics other data
62.38%
-16.06%
of TGTX is owned by hedge funds
159
-7
84.08M
-21.34M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 100000 | 0 |
| Jan 2024 | 0 | 65367 |
| Mar 2024 | 0 | 27000 |
| Jun 2024 | 0 | 25933 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | LONIAL SAGAR director | Common Stock | 16,348 | $16.87 | $275,791 | ||
Sale | LONIAL SAGAR director | Common Stock | 9,585 | $16.39 | $157,098 | ||
Sale | LONIAL SAGAR director | Common Stock | 5,000 | $15.94 | $79,675 | ||
Sale | CHARNEY LAURENCE N director | Common Stock | 22,000 | $15.97 | $351,340 | ||
Sale | CHARNEY LAURENCE N director | Common Stock | 17,500 | $19.03 | $333,025 | ||
Sale | POWER SEAN A officer: CFO | Common Stock | 47,867 | $16.91 | $809,431 | ||
Purchase | WEISS MICHAEL S director, officer.. | COMMON STOCK | 100,000 | $10.13 | $1,013,000 | ||
Purchase | WEISS MICHAEL S director, officer.. | COMMON STOCK | 100,000 | $10.13 | $1,013,000 | ||
Purchase | WEISS MICHAEL S director, officer.. | COMMON STOCK | 100,000 | $10.13 | $1,013,000 | ||
Purchase | WEISS MICHAEL S director, officer.. | COMMON STOCK | 100,000 | $10.13 | $1,013,000 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 5 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Michael S. Weiss Esq. (1966) Chairman, Chief Executive Officer & Pres | $1,630,000 |
Mr. Sean A. Power CPA, CPA (1982) Chief Financial Officer, Corporation Sec. & Treasurer | $509,540 |
TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel
TG Therapeutics: Estimates Could Soon Be Raised Again
Why Investors Should Watch Teva Despite Regional Risks
Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst
TG Therapeutics: Entering 2025 With Increased Investor Expectations
TG Therapeutics: 2025 Revenues Will Smash Expectations
Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI +
TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst
June 2024 New Analysts Cover Uber, TG Therapeutics, CarMax, And More
-
What's the price of TG Therapeutics stock today?
One share of TG Therapeutics stock can currently be purchased for approximately $27.92.
-
When is TG Therapeutics's next earnings date?
Unfortunately, TG Therapeutics's (TGTX) next earnings date is currently unknown.
-
Does TG Therapeutics pay dividends?
No, TG Therapeutics does not pay dividends.
-
How much money does TG Therapeutics make?
TG Therapeutics has a market capitalization of 4.95B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 8290.02% to 233.66M US dollars.
-
What is TG Therapeutics's stock symbol?
TG Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TGTX".
-
What is TG Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of TG Therapeutics?
Shares of TG Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are TG Therapeutics's key executives?
TG Therapeutics's management team includes the following people:
- Mr. Michael S. Weiss Esq. Chairman, Chief Executive Officer & Pres(age: 59, pay: $1,630,000)
- Mr. Sean A. Power CPA, CPA Chief Financial Officer, Corporation Sec. & Treasurer(age: 43, pay: $509,540)
-
How many employees does TG Therapeutics have?
As Jul 2024, TG Therapeutics employs 284 workers, which is 8% more then previous quarter.
-
When TG Therapeutics went public?
TG Therapeutics, Inc. is publicly traded company for more then 15 years since IPO on 3 May 2010.
-
What is TG Therapeutics's official website?
The official website for TG Therapeutics is tgtherapeutics.com.
-
Where are TG Therapeutics's headquarters?
TG Therapeutics is headquartered at 2 Gansevoort Street, New York, NY.
-
How can i contact TG Therapeutics?
TG Therapeutics's mailing address is 2 Gansevoort Street, New York, NY and company can be reached via phone at +212 5544484.
-
What is TG Therapeutics stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for TG Therapeutics in the last 12 months, the avarage price target is $37.5. The average price target represents a 34.31% change from the last price of $27.92.
TG Therapeutics company profile:
TG Therapeutics, Inc.
tgtherapeutics.comExchange:
NASDAQ
Full time employees:
319
Industry:
Biotechnology
Sector:
Healthcare
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
2 Gansevoort Street
New York, NY 10014
New York, NY 10014
CIK: 0001001316
ISIN: US88322Q1085
CUSIP: 88322Q108
